Capmatinib and Ondansetron: Interaction Details
AI-assisted, pharmacist-reviewed · Source data updated Aug 8, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Ondansetron
No brand names on recordCapmatinib
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
What happens
Increased CYP1A2 substrate exposure and an increased risk of adverse reactions
Interaction Deep Dive
Coadministration of capmatinib (CYP1A2 inhibitor) with a CYP1A2 substrate increased CYP1A2 substrate exposure, which may increase the adverse reactions of these substrates. When coadministered with caffeine, the AUC(0 to infinity) of caffeine increased by 134%. If coadministration is unavoidable between capmatinib and CYP1A2 substrates where minimal concentration changes may lead to serious adverse reactions, decrease the CYP1A2 substrate dosage as recommended1.
Why it happens (mechanism)
Inhibition of CYP1A2-mediated metabolism by capmatinib
Literature reports
1 report — tap to read
a) In a drug interaction study, coadministration of capmatinib (CYP1A2 inhibitor) with caffeine (a CYP1A2 substrate) increased caffeine AUC(0 to infinity) by 134% with no change in its Cmax 1.
Common questions
Can I take Capmatinib and Ondansetron together?
Increased CYP1A2 substrate exposure and an increased risk of adverse reactions Always confirm with your pharmacist or prescriber before making any change.
How serious is the Capmatinib and Ondansetron interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
From our Q&A
Real reader questions about these medications, each personally answered by our pharmacist:
Questions for your pharmacist
- Does my dose of Capmatinib or Ondansetron need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (1)
- Product Information: TABRECTA(R) oral tablets, capmatinib oral tablets. Novartis Pharmaceuticals Corporation (per FDA), East Hanover, NJ, 2024. DailyMed
Keep reading about Ondansetron
Keep reading about Capmatinib
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist